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Abstract Cavernous malformations (CCMs) are benign,
well-circumscribed, and mulberry-like vascular malforma-
tions that may be found in the central nervous system in up
to 0.5% of the population. Cavernous malformations can be
sporadic or inherited. The common symptoms are epilepsy,
hemorrhages, focal neurological deficits, and headaches.
However, CCMs are often asymptomatic. The familiar form
is associated with three gene loci, namely 7q21-q22
(CCM1), 7p13-p15 (CCM2), and 3q25.2-q27 (CCM3) and
is inherited as an autosomal dominant trait with incomplete
penetrance. The CCM genes are identified as Krit 1
(CCM1), MGC4607 (CCM2), and PDCD10 (CCM3).
Here, we present the clinical and genetic features of CCMs
in 19 Swiss families. Furthermore, surgical aspects in such
families are also discussed.
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Introduction
Cavernous malformations (CCMs) of the central nervous
system are well-circumscribed, lobulated, mulberry-like,
and often encapsulated structures that can vary greatly in
size [25]. They are found in about 0.5% of the population
and represent approximately 10–20% of cerebral vascular
lesions [22]. Microscopically, CCMs consist of enlarged
thin-walled blood vessels without intervening neural tissue.
Clinically, they may remain asymptomatic, but often
manifest with epileptic seizures, gross hemorrhages, focal
neurological deficits, and/or headache [7, 24, 26].
Cavernous malformations may be sporadic or inherited
in an autosomal dominant fashion with a high penetrance
[9, 11]. While sporadic CCMs are often solitary, the familial
form is usually associated with multiple lesions [26]. In
genetic studies, three genetic loci have been defined [5]:
CCM1 on chromosome 7q21-q22 (MIM 116860) accounting
for 40% of all familial cases [6, 9, 11, 18], CCM2 on
7p13-p15 (MIM 603284) accounting for 13–20% [17, 29],
and CCM3 on 3q25.2-q27 (MIM 603285) for 40% [2].
In this study, we present the clinical and genetic features
of 19 Swiss families with inherited CCMs.
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Patients and methods
The families were ascertained by a national search
procedure performed at eight Swiss regional and university
hospitals. Criteria for inclusion in this study were
neuroradiologically diagnosed and/ or histopathological-
ly proven CCMs of the CNS in at least two family
members. By this search, 19 families of Swiss origin with
inherited CCMs were obtained from five hospitals (Aarau,
Basle, Berne, Lausanne, and Zurich). In the affected
individuals, both clinical and genetic data were analyzed.
If symptomatic parent–offspring pairs were available, we
also measured anticipation by intergenerational compari-
son of mean age at symptom onset. Genetic analyses for
CCM1 and CCM2 have been performed by the use of
methods previously described [10, 17, 28, 29]. Due to
logistic and financial reasons, we focussed on the index
patients for genetic analysis. Type and outcome of
surgical procedures were also presented. This study was
approved by the Committee for the Protection of Human
Subjects at the Dartmouth College, New Hampshire,
USA.
Results
Demographic data
The 19 families comprised a total of 56 affected individuals.
In these families, between two and four generations were
affected. Thirty-three (59%) individuals were females and 23
males. The number of affected individuals per family ranged
from 2 to 6.
Clinicopathological features
Of the 56 affected individuals, 12 (21%) were asymptomatic.
These individuals have been identified in the scope of
family screening. In the 44 symptomatic individuals, the
most frequent manifestations encountered were epilepsy
(16 or 36%), followed by focal neurological deficits (14 or
32%), hemorrhage (8 or 18%), and headache (6 or 14%).
The mean age at symptom onset was 27.9 years (range, 1
to 79 years). Individuals with epilepsy became first
symptomatic (mean age at onset 19.7 years), followed by
headache (29.2 years), focal neurological deficits
(29.3 years), and hemorrhages (40.6 years). Ten affected
symptomatic individuals had an offspring with clinical
symptoms. Of these parent–offspring pairs, the mean age
at first clinical manifestation was 37.8 years in the first
and 20.4 years in the second generation. Of the 56 affected
individuals, 32 (57%) harbored multiple CCMs (range 2 to
78 lesions), whereas, 24 (43%) had a single lesion. Of the
19 index individuals, 12 (63%) harbored multiple lesions
and seven had single ones.
Genetic features
Of 37 individuals, genetic analysis has not been performed
due to financial and logistic reasons. However, genetic
analysis could be performed in 19 individuals representing
all 19 families. Of these, in nine individuals (47%), a
mutation in CCM1 has been found. The observed CCM1
mutations comprised frameshifts in four individuals (44%),
nonsense mutations in three (33%), changes in the invariant
splice junctions and missense mutations in each one (11%
each). Six individuals (32%) had a CCM2 mutation
consisting of two frameshift and one nonsense mutation.
In the remaining individuals, we did not screen for CCM3.
Surgical treatment
None of the 12 asymptomatic individuals have been
operated for their CCMs. Of the 44 symptomatic cases,
24 (55%) were surgically treated. Of these, 14 were
operated on for their medically refractory epilepsy, five
for a hemorrhage, and five for focal neurological deficits.
The mean age at surgery was 29.4 years. All procedures
performed included lesionectomy and in cases with
epilepsy, additional resection of the surrounding hemosid-
erin rim. There was no perioperative mortality, and the
perioperative morbidity was 4% (1/24). Two patients with
epilepsy refused an operation. Of the 14 patients surgically
treated for epilepsy, 11 (78%) became seizure-free postop-
eratively and only three had rare seizures (one to two
seizures per year) following surgery. Of the 11 seizure-free
patients, antiepileptic drugs could be tappered off in three
patients.
Discussion
Familial CCMs of the central nervous system have first
been described 80 years ago. In 1928, Hugo Friedrich Kufs
reported on a family in which he assumed a common
pathological basis in two members [15] (Fig. 1). He
reported on an 81-year-old man in whom multiple cerebral
and hepatic cavernomas have been found in an autopsy. His
daughter presented with an “apoplexia pontis” with a right-
sided hemiparesis and hemihypesthesia at the age of
17 years. Although CCMs have not been pathologically
confirmed in the daughter, Kufs has to be given the credit
for the first description of this entity. By the use of
magnetic resonance imaging, further families have increas-
ingly reported. Thus, since the first description, almost
1,000 families have been reported all over the world [5, 16,
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26]. Despite this large number of families reported, the
prevalence of the inherited form of CCM is still not known
yet. In early “semiepidemiological” studies in hispanics, a
prevalence of inherited CCM of up to 50% has been
suggested [22]. The high prevalence of CCMs in this ethnic
group, however, is due to a “founder mutation” in the
CCM1 gene that caused a sample bias [12, 13]. In later
studies, this high prevalence could not be confirmed for
other ethnic populations. Large epidemiologically based
national studies in France and other studies have shown a
lower but still undetermined prevalence for inherited CCMs
[16, 27]. Here, we report 19 families found in Switzerland
(with a population of 7.5 million) indicating a very low
prevalence. However, our study comprises several method-
ological biases. Firstly, we did not perform screening by
MRI in family members of individuals with CCMs as other
studies have been previously performed [16]. Secondly,
individuals who were not referred to one of the involved
hospitals were not object to our study. Thirdly, we were not
able to detect families with asymptomatic individuals only.
Thus, to determine an accurate prevalence, further epide-
miological studies have to be established.
Clinicopathological features
Clinically, inherited CCMs do not differ from the sporadic
form. Both in sporadic and inherited CCMs 20% to 50% of
patients with CCMs remain asymptomatic [3, 19, 26].
Between 41% and 59% of symptomatic cavernomas are
associated with recurrent epileptic seizures, which are drug
resistant in about 40% of cases [3, 4]. The estimated risk for
seizure development was estimated at 1.51% per patient and
year, or 2.48% per lesion and year in patients with multiple
lesions [7]. CCMs may also cause major hemorrhages in
9% to 70% with a reported annual risk between 1% to 4%,
while being associated with a higher risk of hemorrhage
after an initial hemorrhagic event and in localizations
involving deep structures or the brain stem [3, 23, 27].
Other clinical manifestations are focal neurologic deficits
and headache [7, 20, 21]. Similar clinical data have been
reported for familial CCMs. In a literature review of 109
families with 379 individuals with inherited CCMs, 91
(24%) were asymptomatic and 288 (76%) presented with
symptoms comprising epileptic seizures (in 43%), followed
by major hemorrhages (in 28%), chronic headache (in 23%),
or focal neurological deficits (in 15%) [26]. In our series,
clinical features were in line with these previous studies.
Here, we also analyzed the clinical data for the
phenomenon of anticipation. The term “anticipation” refers
to a progressively earlier age of symptom onset and/or
increase in severity of an inherited disease in successive
generations. In a previous study, we have shown that the
mean age at first clinical manifestation decreased across
generations from 32.7 years in the first generation to
18.0 years in the second generation then to 7.7 years in the
third generation [26]. In this study, ten parent–offspring pairs
could be analyzed for anticipation. These intergenerational
pairs showed a decreased mean age at symptom onset in the
offspring (20.4 years) compared to the parents (37.8 years).
While expansion of unstable trinucleotide repeat has been
found as the cause for anticipation in various neurological
diseases, the cause for this phenomenon in CCMs is still not
known [26].
In our series, 57% of the affected individuals harbored
multiple CCMs, and 43% had single malformations. This
corresponds to previous studies reporting multiple lesions in
up to 69% of familial cases [26]. These numbers support
previous findings that carriers of multiple CCMs are more
often associated with the familial form of this disease, but a
solitary lesion does not exclude inheritance [26]. This
awareness of this finding is important for genetic counseling.
Genetic aspects and counseling
Genetic analysis identified three CCM loci: CCM1 on
chromosome 7q21-q22 accounting for 40% of all familial
cases, CCM2 on 7p13-p15 accounting for 13–20%, and
CCM3 on 3q25.2-q27 for up to 40% [5, 29].
The gene CCM1 encodes for a 736 amino acids protein
called the "Krev Interaction Trapped 1" (Krit 1) protein.
Krit1 contains three ankyrin repeats, a FERM (Band 4.1,
ezrin, radixin, and moesin) domain and a NPXY (Asn-Pro-
X-Tyr) motif. Molecular studies show that the NPXY motif
seem to modulate a strong interaction with the integrin
cytoplasmic domain-associated protein 1 (icap1), suggesting
that this protein might be involved in bidirectional signaling
between the integrin and the cytoskeleton in CCM1
pathogenesis [31]. In addition, Krit1 has been shown to be
a microtubule-associated protein that may help determine
endothelial cell shape and function in response to cell–cell
and cell–matrix interactions by guiding cytoskeletal structure
Fig. 1 Picture of Hugo Friedrich Kufs who first described the
inherited form of cavernous malformations in 1928.
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[14]. The CCM2 gene found at locus 7p13-p15 encodes for
the “Malcavernin” protein [8, 17]. “Malcavernin” is a similar
protein as the Krit 1 binding partner ICAP1, a protein with a
phosphotyrosin binding domain [32]. Recently, the PDCD10
(Programmed Cell Death 10) gene also called TFAR15 has
been identified as the CCM3 gene [2]. Although the product
and function of PDCD10 is still not known, it is thought to
interact with angiogenesis.
In our series, genetic analysis could be performed in 19
individuals. The mutations found were mainly in the CCM1
gene (in nine individuals) and less commonly in CCM2 (in
six individuals). Type of mutations were reported in detail
elsewhere [10, 28, 30]. In four individuals, neither in
CCM1 nor in CCM2 mutations have been found indicating a
mutation in CCM3. Recently, some studies have suggested
that an additional gene (CCM4) might be involved since
there were some affected in whom no mutations could be
detected in the three known CCM genes.
Surgical outcome
Since CCMs are often symptomatic, a surgical treatment
becomes mandatory. There is a large variety of studies
reporting excellent surgical outcome following removal of
CCMs [1, 3, 7, 21]. Thus, in a large series of 72 patients,
there was no mortality, and the immediate perioperative
morbidity rate was 29.2% (21/72), while the rate of long-
term morbidity was 5.5% (4/72). Similarly, in our series of
familial CCMs, there was also no mortality, and the long-
term morbidity was 4%. Surgery has particularly proven to
be an effective treatment in CCMs manifesting with
epilepsy. Patients become seizure-free in about 70% to
80% [1, 3]. In our patients, 11 of 14 (78%) became
seizure-free. This excellent result gets endorsed by the fact
that antiepileptic drugs could be tapered off after surgery
in three patients. None of our patients have been operated
on for multiple CCMs. Analogously to sporadic cases in
patients with multiple CCMs, the question is under debate
whether more than the symptomatic malformation should
be removed. So far, there are no guidelines, and often, the
neurosurgeon’s philosophy is decisive. Another important
issue is the management of asymptomatic affected
individuals. Here, the annual risk of hemorrhages or
seizures has to be weighed in contrast to the risk of an
operation. Though, there are no strict guidelines in either
of these cases, the indication for surgery should be given
rather cautiously.
Conclusion
Although accurate prevalence data are still not available, the
familial occurrence of CCMs seems to be underestimated.
Therefore, each individual with CCMs has to be thoroughly
interviewed for a positive family history. However, the
identification of other affected family members might be
facilitated in the future by the use of increasingly available
genetic testing. Current genetic studies focuses on the search
for additional genes causing CCMs. While CCMs may
remain asymptomatic, they are often symptomatic and an
operation may become mandatory.
In the management of this entity, some questions still
have to be answered. Thus, it is still debatable whether
asymptomatic individuals with familial CCMs should also
be surgically treated. Furthermore, the methodological
drawbacks of our study mentioned above might be reduced
by establishing a center for this disorder in Switzerland.
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Comments
Daniele Rigamonti, Baltimore, USA
This is an interesting study detailing the presumed prevalence of
inherited cerebral cavernous malformation in Switzerland.
The female/male ratio instead of the expected 1:1 is 3:2; the ratio
between multiple/single lesions is approximately 3:2.
Due to financial and logistic reasons, only 19 (34%) individuals
out of the 56 affected individuals underwent genetic testing; nine
individuals (47%) had mutations in the CCM1 gene, six individuals
(31.5%) had mutations in CCM2, and 21% (four individuals) have
neither CCM1 nor CCM2 mutations. The authors suggest that these
four individuals (21%) might have mutation in CCM3.
This again is somewhat at odds with the reported prevalence of the
genetic abnormalities in the published literature that suggests that
CCM1 (on chromosome 7q21-q22) accounts for 40% of all familial
cases, CCM2 (on 7p13-p15) accounts for 13–20%, and CCM3 (on
3q25.2-q27) accounts for 40%.
Symptoms presentation is typical, and surgical results are quite
good with 4% morbidity and 78% of patients with intractable epilepsy
rendered seizures-free by the surgery.
The authors nicely touch upon the importance of genetic
counseling and careful neurosurgical management approach.
Oguzkan Sürücü, Zurich, Switzerland
In this publication, Graeni et al. have retrospectively reviewed
clinical and genetic data of patients with familial cerebral cavernous
malformations collected from five, mainly universitary hospitals in
Switzerland. Genetic features from 19 of 56 affected individuals have
been published already elsewhere and are not presented in detail here.
The focus is on clinicopathological data which is summarized
adequately. Surgical indications, therapy and good outcome, e.g. for
epilepsy, matches with previous studies. As stated in the conclusion
this study is not representative for accurate prevalence data for
Switzerland. But it points out that comprehensive management of
patients with familial cerebral cavernomas requires an interdisciplin-
ary approach from neurological, neurosurgical and genetically aspects
in centres with broad experience in the treatment of this disease. This
is of major interest for these patients who are often confused by
ambiguous statements from medical staff, press or internet.
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